Loading
Latest filing published 29 Sept 2026 for XSpray Pharma AB (publ), €42k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Blake Leitch appears in our data through filings on XSpray Pharma AB (publ) shares, published by Finansinspektionen. Over a trading history stretching from 12 June 2026 to 28 September 2026, the count stands at 5 filings.
Every open-market trade on record is a purchase: 4 purchases worth €170k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant.
Half of the purchases are above €51k and half below.
On 29 September 2026 came the latest disclosure, an open-market purchase for €42k in XSpray Pharma AB (publ). The median gap between a trade and its publication by Finansinspektionen is 1 day. For comparison, MAR article 19 gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations